Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Bryan Wei Chen¹, Wei Chen¹, Hui Liang¹, Hao Liu¹, Chao Liang¹, Xiao Zhi¹, Li-qiang Hu¹, Xia-Zhen Yu¹, Tao Wei¹, Tao Ma¹, Fei Xue², Lei Zheng³,⁴, Bin Zhao⁵, Xin-Hua Feng⁵, Xue-li Bai¹, and Ting-bo Liang¹,⁶

Abstract

mTOR is aberrantly activated in hepatocellular carcinoma (HCC) and plays pivotal roles in tumorigenesis and chemoresistance. Rapamycin has been reported to exert antitumor activity in HCC and sensitizes HCC cells to cytotoxic agents. However, due to negative feedback activation of AKT after mTOR complex 1 (mTORC1) inhibition, simultaneous targeting of mTORC1/2 may be more effective. In this study, we examined the interaction between the dual mTORC1/2 inhibitor OSI-027 and doxorubicin in vitro and in vivo. OSI-027 was found to reduce phosphorylation of both mTORC1 and mTORC2 substrates, including 4E-BP1, p70S6K, and AKT (Ser473), and inhibit HCC cell proliferation. Similar to OSI-027 treatment, knockdown of mTORC2 induced G0–G1 phase cell-cycle arrest. In contrast, rapamycin or knockdown of mTORC1 increased phosphorylation of AKT (Ser473), yet had little antiproliferative effect. Notably, OSI-027 synergized with doxorubicin for the antiproliferative efficacy in a manner dependent on MDR1 expression in HCC cells. The synergistic antitumor effect of OSI-027 and doxorubicin was also observed in a HCC xenograft mouse model. Moreover, AKT was required for OSI-027-induced cell-cycle arrest and downregulation of MDR1. Our findings provide a rationale for dual mTORC1/mTORC2 inhibitors, such as OSI-027, as monotherapy or in combination with cytotoxic agents to treat HCC.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and second leading cause of cancer-related deaths worldwide (1). Surgery is often unsuitable in advanced disease, although surgical resection or liver transplantations are suitable therapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2). Doxorubicin is widely used to treat HCC (3, 4), despite the fact that monotherapeutic approaches for early-stage HCC (2).

mTOR is aberrantly activated in human HCC (13) and plays a pivotal role in HCC tumorigenesis (14). Targeting mTOR using rapamycin can sensitize tumor cells to cisplatin (15), doxorubicin (16), and other targeted therapeutic agents such as histone deacetylase inhibitors (17). However, mTORC1 inhibition activates mTORC2 signaling via disengaging the p70S6K-define (IRS) negative feedback loop, thus limiting the antitumor efficacy of
this strategy (18). Therefore, efforts are now underway to identify a mechanism of targeting mTORC2 in cancer.

OSI-027, a novel ATP-competitive inhibitor of mTOR, inhibits both components of the mTOR complex and has demonstrated potent anticancer effects in colorectal cancer, breast cancer, and lymphoma (19–21). However, OSI-027 has been reported to enhance the cytotoxicity of cisplatin and EGFR inhibitor (EGFRI) in breast cancer and head/neck squamous cell carcinoma, respectively (22, 23). Given that rapamycin and rapalog (RAD001) exert additive antitumor effects when administered with doxorubicin in preclinical models of HCC (16, 24), we investigated the antitumor effect of OSI-027 alone and in combination with doxorubicin. In the present study, we demonstrate that inhibition of mTORC2, but not mTORC1, abrogated hyperactivation of AKT and consequently promoted cell-cycle arrest in a panel of HCC lines. Furthermore, inhibition of mTORC2 potently sensitized HCC cancer cells to doxorubicin both in vitro and in vivo. This study provides a rationale for the use of dual mTORC1/mTORC2 inhibitors as a monotherapy or in combination with traditional chemotherapeutic agents for the treatment of HCC.

Materials and Methods

Cell lines and cell culture

Human HCC cell lines and HL-7702 cells were obtained from Shanghai Institute for Biological Sciences, China on February 10, 2012. HepG2 and SK-Hep1 cells were cultured in high glucose DMEM (Gibco) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich); Hep3B cells, MEM (Lonza) supplemented with 10% FBS and 1% penicillin/streptomycin; HepG2, Hep3B, and HL-7702 cells, RPMI-1640 (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2 and were used within 3 months of resuscitation. We have had all the cell lines authenticated by a professional biotechnology company in 2014.

Reagents

OSI-027 and GSK6906793 were purchased from Selleck; rapamycin, doxorubicin, MG-132, and cycloheximide (CIX) from Sigma-Aldrich. Stock solutions were prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich), stored at −20°C, and diluted in fresh medium for each experiment. The final concentration of DMSO did not exceed 0.5% in any experiment.

Cell viability and proliferation assays

To evaluate relative cell viability, HCC cells (5,000 per well) were seeded into 96-well microplates, incubated overnight, the culture medium was replaced with complete media containing diverse concentrations of rapamycin (0.1, 0.4, 1.6, 6.4, 25.6, 102.4, and 409.6 μmol/L) or OSI-027 (0.3125, 0.625, 1.25, 2.5, 5.0, 10, and 20 μmol/L) for 48 hours, then the cell counting kit-8 assay (CCK-8; KeyGEN) was conducted following the manufacturer’s instructions. The dosages of OSI-027 to treat HL-7702 cells were 0.25, 0.50, 1.0, 2.0, 4.0, 8.0, and 16 μmol/L. Cell viability was expressed relative to untreated control cells.

To evaluate cell proliferation, SNU-387 cells were treated with 10 μmol/L rapamycin or 2.0, 5.0, and 10 μmol/L OSI-027, respectively, while other four cell lines were incubated with 2.0 μmol/L rapamycin or indicated concentrations of OSI-027 (0.5, 1.0, 2.0 μmol/L). Then cells were assayed using the Click-IT 5-ethyl-2-oxo-deoxyuridine (EdU) Imaging Kit (Invitrogen) following the manufacturer’s instructions and counterstained with Hoechst 33342. The percentage of proliferating cells in five random fields of view per slide was determined under an inverted fluorescence microscope (Olympus) and expressed relative to untreated control cells.

Apoptosis and cell-cycle analysis

Cells were treated with OSI-027 (5.0, 10, and 20 μmol/L for SNU-387, 1.0, 2.0, and 4.0 μmol/L for other four HCC cell lines) for 48 hours, stained using the Annexin V-PE/7AAD apoptosis kit (BD Biosciences) according to the manufacturer’s protocol, and analyzed using a BD FACS Caliber flow cytometer using BD Cell Quest software.

For cell-cycle analysis, cells were treated with DMSO, rapamycin (20 μmol/L), OSI-027 (and 4 μmol/L) for other four HCC cell lines) or OSI-027 as described for apoptosis assay for 48 hours, stained with propidium iodide (PI; Dawen) and analyzed by flow cytometry. Quantitative cell-cycle analysis was conducted using ModFit software (Verity Software House). Cell proliferation was expressed as the percentage of S + G2–M phase cells (25).

Drug combination analysis

Multiple drug-effect analysis was used to evaluate the effects of combined drug treatment, as described by Chou and Talalay (26). The results of the CCK-8 assay were calculated using the following equation: combination index (CI) = (D1)/(Dx)1 + (D2)/(Dx)2, where (Dx)1 and (Dx)2 are the concentrations of drug 1 and drug 2 alone that achieve effect level, D1 and D2 are the concentrations of drug 1 and drug 2 in combination that give the same effect level, A CI < 1 indicates synergism; CI = 1 and CI > 1 indicate an additive effect and antagonism, respectively.

RNAi

Human siRNAs specific for Raptor and Rictor were synthesized by GenePharma Co., Ltd. Detailed information of Raptor and Rictor siRNAs is described in the Supplementary Materials and Methods. MDR1, mTOR, and AKT-specific siRNAs were purchased from Cell Signaling Technology. Cells were transfected with siRNAs using Roche X-tremeGENE 9 (Roche Applied Science) following the manufacturer’s instructions. Transfection medium was replaced with complete medium 6 hours later, and efficiency of siRNA knockdown was confirmed by immunoblotting.

Quantitative real-time PCR

Cells were treated with DMSO, OSI-027 (double the IC50 concentrations), doxorubicin (IC50 concentrations), or OSI-027 plus doxorubicin for 24 hours, and total RNA was extracted using TRIzol Reagent (Invitrogen) and reverse transcribed using the Prime Script reagent RT Kit (Takara). Primers for MDR1 were designed and purchased from Takara Biosystems Inc). MDR1 mRNA expression was normalized to β-actin and determined using the comparative 2−ΔΔCt method (27). Detailed sequences of primers for MDR1 and β-actin are given in the Supplementary Materials and Methods.

Immunoblotting

Immunoblotting was performed using standard protocols. Briefly, 20 μg protein lysates were fractionated on 8% to 12% Tris-glycine polyacrylamide gels, transferred to polyvinylidene
mTORC2 Inhibition Enhances the Cytoxicity of Doxorubicin

difluoride membranes, blocked, incubated overnight with primary antibodies (all 1:1,000 dilution) followed by the appropriate horse-radish peroxidase (HRP)-conjugated secondary antibody (1:2,000 dilution), and developed using enhanced chemiluminescence. All antibodies were obtained from Cell Signaling Technology, with the exception of anti-Cyclin D1 (Epitomics) and the HRP-conjugated secondary antibodies (Beyotime Institute of Biotechnology).

Xenograft study
Male athymic nude mice (3–4 week old; 18–20 g) were purchased from Shanghai Experimental Animal Centre and housed in a specific pathogen-free facility. Animal care was in compliance with the guidelines of the Animal Ethics Committee of Zhejiang University. Mice were inoculated subcutaneously in the left flank with 10^6 Huh-7 cells in 100 μl saline solution.

Two weeks after tumor inoculation, twenty tumor-bearing mice were divided into four groups (n = 5 each): control group; OSI-027 group [orally administered 30 mg/kg OSI-027 in 20% Trappeoil [(CTD Holdings Inc)] every other day; doxorubicin group, injected via the caudal vein with 2 mg/kg doxorubicin in saline solution every other day; and combination group, administered 30 mg/kg OSI-027 and 2 mg/kg doxorubicin every other day. Tumor volume and body weight were measured every 2 days. Tumor volume was calculated using (L × W²)/2, where L is the diameter of the longest dimension and W is the orthogonal diameter. Relative tumor volume (RTV) was calculated using Vt/V0, where Vt is the tumor volume of all the groups at indicated time t and V0 is the original tumor volume of the animals. After 2 weeks, the mice were euthanized by cervical dislocation. Tumor growth inhibition (TGI%) was calculated using \( \frac{1 - (t0/t1)}{C0/C1} \times 100 \), where t0 is the tumor volume of the treated group at indicated time t, t1 is the original tumor volume of the treated animal, C0 is median tumor volume of untreated mice at time t, and C1 is the median original tumor volume of the control group.

Results
OSI-027 inhibits the growth of HCC cells in a concentration-dependent manner in vitro
In agreement with a previous study (28), the CCK-8 assay demonstrated rapamycin hardly had any cytoxicity (IC50 > 100 mmol/L) in all HCC cell lines tested (Fig. 1A). In contrast, the cytotoxicity of OSI-027 varied in HCC cell lines, with IC50 values ranging from 1 to 8 μmol/L (Fig. 1B; Table 1). Moreover, OSI-027 had a lower cytotoxicity in HL-7702 normal human liver cells (IC50 > 25 μmol/L) than HCC cells (Fig. 1C).

As the CCK-8 assay cannot distinguish between cell-cycle arrest and cytotoxicity in continuously cycling cell lines, we used the EdU thymidine analog incorporation assay (29) to estimate proliferation in HCC cells treated with rapamycin or OSI-027 for 48 hours. Consistent with the CCK-8 assay, rapamycin did not significantly affect HCC cell proliferation, whereas OSI-027 significantly inhibited HCC cell proliferation in a dose-dependent manner (Fig. 1D and E and Supplementary Fig. S1A–S1C).

OSI-027, but not rapamycin, inhibits both the mTORC1 and mTORC2 signaling cascades in HCC cells
We investigated the mechanism underlying the increased cytotoxicity of OSI-027 compared with rapamycin (Fig. 1). Immuno-blotting demonstrated ubiquitous basal activation of mTOR-dependent signaling in HCC cells, as indicated by high levels of phosphorylated mTOR substrates (Fig. 2A). Exposure of HCC cells to OSI-027 for 8 hours completely inhibited phosphorylation of mTOR on Ser2481, the marker of mTORC2 complex activity, and its substrate AKT (Ser473) in a dose-dependent fashion. In contrast, rapamycin inhibited mTORC1 activity (phosphorylation of Ser448) without affecting mTOR2 activity (Ser2481), and also markedly increased AKT phosphorylation (Ser473; Fig. 2B–F; lanes 1, 2, 4). OSI-027 inhibited the phosphorylation of all mTORC1 substrates examined, including 4E-BP1 (Thr37/46) and p70S6K (Thr389). In contrast, rapamycin inhibited phosphorylation of p70S6K, but not 4E-BP1 (Fig. 2B–F; lanes 6, 8). Therefore, OSI-027 efficiently inhibits both the mTORC1 and mTORC2 signaling cascades in HCC cells, whereas rapamycin partially inhibits mTORC1 but does not inhibit mTORC2, even at relatively high doses in the micromolar range. These results are consistent with previous studies on rapamycin (30, 31) and may explain the poor efficacy of rapamycin in vitro.

OSI-027, but not rapamycin, induces cell-cycle arrest in HCC cells
Considering the significance of mTOR in the regulation of cell metabolism, cell-cycle progression and survival (32–35), we investigated the antiproliferative effect of OSI-027 further. Annexin V staining and flow cytometry demonstrated treatment with OSI-027 for 48 hours (Supplementary Fig. S2A and S2B) did not induce apoptosis, as previously reported (19, 21, 36). Nevertheless, OSI-027 increased the proportion of SNU-449 cells in the G0–G1 phase (from 67.29% to 89.31%) in a dose-dependent manner (Fig. 3A). In contrast, rapamycin did not significantly affect the G0–G1 ratio compared with DMSO control-treated cells (Fig. 3A). Similar results were obtained in the other four HCC cell lines, except for SNU-387 cells in which rapamycin induced a low level of cell-cycle arrest (Fig. 3A and Supplementary Fig. S3A–S3C). In agreement with the cell-cycle distribution analysis, OSI-027 significantly reduced the expression of Cyclin D1 and CDK4 in all five HCC cell lines, whereas rapamycin did not significantly affect the expression of these cell cycle-associated proteins (Fig. 3B and Supplementary Fig. S 3D).

Targeting of mTORC2, rather than mTORC1, promotes G0–G1-phase arrest in HCC cell lines
To further identify whether mTORC1 or mTORC2 participates in the induction of cell-cycle arrest by OSI-027, the effects of Raport, Rictor, and mTOR on cell-cycle progression were examined. Raptor is short for regulatory-associated protein of mTOR and regarded as one of the components of mTORC1. Rictor serves as a binding platform where substrates are presented to mTOR for subsequent activation of mTORC1 (37). As for rapamycin-insensitive companion of mTOR (Rictor), it contributes to the structural foundation of mTORC2. And in the absence of Rictor, mTORC2 becomes inactive (38). Knockdown of Rictor or mTOR clearly increased the number of G0–G1 phase cells in all HCC cell lines tested, whereas knockdown of Raptor had no significant effect (Fig. 3C and D and Supplementary Fig. S4A–S4C). Furthermore, knockdown of Rictor or mTOR, but not Raptor, simultaneously reduced Cyclin D1 expression and AKT phosphorylation (Ser473) in Hep-3B and SNU-449 cells (Fig. 3E; lanes 4, 5). Knockdown of Raptor even slightly increased AKT phosphorylation (Ser473; Fig. 3E; lane 4), consistent with activation of AKT

www.aacjournals.org Mol Cancer Ther; 14(8) August 2015 1807

On June 20, 2017. © 2015 American Association for Cancer Research.
by rapamycin (Fig. 2B–F). These data suggest that targeting of mTORC2, but not mTORC1, promotes G0–G1-phase arrest and phosphorylation of the hydrophobic motif of AKT may be required to maintain Cyclin D1 expression and promote cell-cycle progression in HCC cells.

OSI-027 synergistically enhances the efficacy of doxorubicin via reversing doxorubicin-induced upregulation of MDR1

Multidrug resistance protein 1 (MDR1) plays a role in the doxorubicin resistance of HCC cell lines (39). Given that marked downregulation of MDR1 was observed in Rictor-silenced HCC Figure 1.

**Table 1.** IC50 values and statistical analyses of OSI-027 and doxorubicin (DOX) treatments in HCC cell lines and HL-7702

<table>
<thead>
<tr>
<th>HCC cell line</th>
<th>OSI-027 IC50 (μmol/L)a</th>
<th>DOX IC50 (μmol/L)</th>
<th>OSI-027 + DOX IC50 (μmol/L)</th>
<th>Combination index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huh-7</td>
<td>1.613 (1.445–1.782)</td>
<td>0.6490 (0.5959–0.7022)</td>
<td>OSI 0.3857 (0.3685–0.4028) DOX 0.3857 (0.3685–0.4028)</td>
<td>0.8353</td>
</tr>
<tr>
<td>Hep-3B</td>
<td>1.051 (0.8065–1.295)</td>
<td>1.157 (1.107–1.206)</td>
<td>OSI 0.3551 (0.2977–0.4125) DOX 0.3551 (0.2977–0.4125)</td>
<td>0.6448</td>
</tr>
<tr>
<td>SK-Hep1</td>
<td>1.303 (1.175–1.432)</td>
<td>0.6720 (0.613–0.7306)</td>
<td>OSI 0.7423 (0.6870–0.7977) DOX 0.1485 (0.1374–0.1595)</td>
<td>0.7907</td>
</tr>
<tr>
<td>SNU-449</td>
<td>2.063 (1.975–2.150)</td>
<td>1.964 (1.831–2.098)</td>
<td>OSI 0.05758 (0.04519–0.06997) DOX 1.152 (1.052–1.252)</td>
<td>0.6145</td>
</tr>
<tr>
<td>SNU-387</td>
<td>8.728 (7.486–9.969)</td>
<td>1.063 (0.9927–1.134)</td>
<td>OSI 0.9397 (0.8569–1.0233) DOX 0.4696 (0.4363–0.5029)</td>
<td>0.5494</td>
</tr>
<tr>
<td>HL-7702</td>
<td>26.07 (16.85–35.30)</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

*IC50 values show OSI-027 and doxorubicin concentration [μmol/L, mean (95% confidence intervals)].
cells (Fig. 3E; lane 6), we examined whether the combination of OSI-027 and doxorubicin led to an additive or synergistic effect. Drug combination index (CI) analysis is a generalized method for analyzing the effects of multiple drugs and identifying addition, synergism, and antagonism. We treated HCC cells with decreasing half-log concentrations of OSI-027, doxorubicin, or a combination of both. The CCK-8 assay was performed and the data were analyzed using method of Chou and Talalay, as described in Materials and Methods. The dose-response curves demonstrated the combined treatment resulted in an enhanced, synergistic effect (CI values ranging from 0.5494 to 0.8333; Fig. 4A; Table 1). Immunoblotting demonstrated downregulation of MDR1 when the cells were treated with approximately double the IC50 concentrations of OSI-027 for 24 h (Fig. 4B). Moreover, upregulation of MDR1 induced by doxorubicin could be reversed by the dual mTORC1/mTORC2 inhibitor OSI-027 (Fig. 4B), especially in Huh-7 and Hep-3B cells. Real-time qRT-PCR confirmed the Western blotting results; the relative expression of MDR1 mRNA reduced by approximately half in OSI-027–treated cells (except in SK-Hep1 cells; Fig. 4C). Furthermore, OSI-027 potently reversed the high levels of MDR1 mRNA expression induced by doxorubicin (Fig. 4C).

The combination of OSI-027 and doxorubicin significantly enhances tumor growth inhibition in HCC in vivo

OSI-027 reverses the high levels of MDR1 expression induced by doxorubicin via inhibiting the synthesis rather than promoting its degradation.

Nude mice were inoculated with a representative HCC cell line, Huh-7, and randomized to one of four treatment groups (control, OSI-027 alone, doxorubicin alone, or OSI-027 plus doxorubicin).
Tumor growth was significantly delayed in the group receiving both OSI-027 plus doxorubicin compared with either treatment alone or the vehicle control (Fig. 5A and B), indicative of a synergistic effect. In comparison with monotherapy, the combination of OSI-027 plus doxorubicin increased the relative tumor-inhibitory rate from approximately 55% to 80.11% (Fig. 5C). Interestingly, OSI-027 alone exhibited a similar antitumor efficacy to doxorubicin, the typical chemotherapeutic drug for HCC, with no significant difference between the tumor volumes or tumor-inhibitory rate of these groups (Fig. 5B and C).

OSI-027 was well tolerated using this schedule, with no animals requiring euthanasia for severe weight loss or signs of other toxicities, though the mice receiving OSI-027 did experience modest weight loss. Moreover, the combination of OSI-027 plus doxorubicin did not result in additive toxicity compared with either treatment alone (Fig. 5D).

Cell-cycle arrest induced by targeting mTORC2 and the reversal of MDR1 expression induced by OSI-027 are both AKT dependent

Given that the downregulation of Cyclin D1/CDK4 and MDR1 coincided with decreased AKT phosphorylation (Ser473), we examined the role of AKT in these processes. As expected, knockdown of AKT using a siRNA resulted in a robust reduction in AKT phosphorylation (Ser473) and simultaneously downregulated Cyclin D1 (Fig. 6A). Flow cytometry revealed induction of G0–G1-phase arrest after knockdown of AKT in the four HCC cell lines tested compared with NC siRNA-transfected cells (Fig. 6B and C and Supplementary Fig. S6A–6C); this effect was almost of the same magnitude as the G0–G1-phase arrest induced by knockdown of Rictor/mTOR (Fig. 3A). Knockdown of AKT also markedly downregulated MDR1 (Fig. 6A). Therefore, the cell-cycle arrest, downregulation of Cyclin D1, and reversal of MDR1 expression.
Figure 4. OSI-027 synergizes the efficacy of doxorubicin via reversing the upregulation of MDR1 induced by doxorubicin. A, dose-response curves for HCC cells treated with OSI-027, doxorubicin, or a combination of both for 48 hours. Immunoblotting analysis (B) and RT-PCR analysis of MDR1 expression (C) in HCC cells treated with OSI-027 (OSI, double the IC50 concentrations for each cell line), doxorubicin (IC50 concentrations), or a combination of both for 24 hours. GAPDH was used as a protein loading control. *P < 0.05; ** and ###, P < 0.01, one-way ANOVA. D, immunoblotting analysis of MDR1 in HCC cells treated with (a) 1 μmol/L MG-132 or (b) 100 μg/mL cycloheximide (CHX) in the presence or absence of OSI-027 (double the IC50 concentrations) for 24 hours. E, immunoblotting analysis of the efficiency of MDR1 siRNA-mediated knockdown compared to control cells (NC). F, dose-effect curves for OSI-027, doxorubicin, and the combination of both drugs in (a) control cells and (b) MDR1-knockdown Hep-3B cells at 48 hours.
induced by inhibition of mTORC2 using OSI-027 are AKT dependent.

Discussion

As a crucial component of the PI3K/AKT pathway that plays a critical role in oncogenesis, mTOR is aberrantly activated in most types of cancer, including human HCC. Increased expression of total p70S6K correlated with activation of mTOR in almost half of patients with HCC (33 out of 73; ref. 13). Consistent with the early study, we found that mTOR and p-mTOR were both overexpressed in either tumor or peritumor tissue compared with normal liver tissue in 60% of the patients detected, indicating the activation of mTOR in HCC (Supplementary Fig. S7). In addition, chromosomal gains in Rictor and positive p-RPS6 staining correlated with tumor recurrence in a larger cohort of patients with HCC (14). In this study, we observed that, though OSI-027 also targets mTORC1, OSI-027 inhibited proliferation and promoted cell-cycle arrest via inhibition of mTORC2, suggesting that mTORC2 plays a critical role in the maintenance of cell viability. We also demonstrated that by inhibiting both mTORC1 and mTORC2, OSI-027 may outperform rapamycin as an anticancer agent. Moreover, OSI-027 exerted a synergistic antitumor effect when combined with doxorubicin. Taken together, this study offers a rationale for clinical testing of mTORC1/mTORC2 inhibitors as monotherapy or concurrently with doxorubicin.

Rapalogs have displayed significant antitumor activity in renal cell carcinoma (41) and have been approved by the U.S. Food and Drug Administration for clinical use. We previously demonstrated that inhibition of mTOR using rapamycin delayed HCC xenograft tumor growth in vivo (42). However, we here found that rapamycin hardly exerted an anticancer effect in HCC in vitro (Fig. 1A and D). These seemingly contradictory findings can be explained by the different microenvironments of in vitro experiments and rodent xenograft models. Inhibition...
of mTOR using rapamycin significantly reduces HCC and renal cell carcinoma xenograft tumor growth via exerting an antiangiogenic effect (28, 39), and we previously reported that differentiation of monocytes into antitumor M1 macrophages may also participate in the antiangiogenic effect of rapamycin in HCC in vivo (42). In contrast, the present study demonstrated that all of the HCC cell lines tested were sensitive to the antiproliferative effects of mTORC1/mTORC2 inhibition using OSI-027. However, SNU-387 cells exhibited relatively low mTORC2 activity and decreased AKT phosphorylation on S473 (Fig. 2A), which may explain the lower sensitivity of this cell line to OSI-027.

We observed that OSI-027 did not induce apoptosis in HCC cells. OSI-027 induced apoptosis in only three of 22 various cell lines in one study and one of three bladder cancer cell lines in a separate study (19, 36), indicating that apoptosis is not a universal mode of action for this agent. However, inhibition of mTORC1/mTORC2 strongly induced apoptosis when combined with cytotoxic agents such as cisplatin or histone deacetylase inhibitors (17, 22), although we did not examine these combinations in HCC. However, these observations support the ability of mTOR inhibitors to promote apoptosis when administered with other drug combinations.

Targeted inhibition of mTORC2, but not mTORC1, potently prevented cells from transitioning from the G0–G1 phase to S phase (Fig. 3C–E). Further experiments demonstrated that AKT played a critical role in this complex process (Fig. 6). Numerous studies have demonstrated that mTORC2 regulates cell-cycle progression (43, 44); however, the precise mechanisms were poorly characterized. Previous studies reported that targeting mTORC2 suppresses Cyclin D1 translation via suppressing recruitment of Cyclin D1 mRNA to polysomes in acute myeloid leukemia and BCR-ABL–expressing chronic myeloid leukemia cells (45, 46). This mechanism is plausible, as the translational repressor 4E-BP1 that regulates cap-dependent mRNA translation is also deactivated by inhibition of mTORC2 (7, 8). However, decreased phosphorylation of AKT (S473) induced by inhibition of mTORC2 resulted in G0–G1 phase arrest and coincided with downregulation of Cyclin D1. Further investigation is urgently needed to elucidate the precise relationship between AKT and 4E-BP1 in cell-cycle progression.

The ability of hepatoma cells to become resistant to cytotoxic agents remains a significant hurdle to chemotherapy. Intrinsic or acquired multidrug resistances (MDR) are major causes of chemoresistance, especially to doxorubicin. The most extensively studied factor associated with MDR is increased expression of P-glycoprotein (also known as ABCB1 or MDR1; ref. 39), which is encoded by MDR1. Arceci and colleagues reported that rapamycin can reverse the MDR phenotype in human T-cell lymphoblastic leukemia cell lines (47), and increased activation of the PI3K/mTOR pathway was recently associated with overexpression of MDR1 in HCC (48). However, the effect of mTORC2 inhibition on MDR1 expression remained unknown. The present study demonstrates that OSI-027 reverses the overexpression of MDR1 induced by doxorubicin in HCC cells. Furthermore, inhibition of mTORC2 may mainly be responsible for this effect (Fig. 3E). We did not examine whether rapamycin exerts a similar effect on MDR1; however, knockdown of Raptor indicated that inhibition of mTORC1 alone had limited effect on MDR1 expression (Fig. 3E). These results indicate that PI3K/mTOR signaling regulates MDR1 via a number of mechanisms in different human cancer cells.

We then investigated how OSI-027 reduced the expression of MDR1. OSI-027 also downregulated MDR1 mRNA expression (Fig. 4C), thus suppression of cap-dependent mRNA translation of the MDR1 gene secondary to decreased phosphorylation...
References

mTORC2 Inhibition Enhances the Cytotoxicity of Doxorubicin


Molecular Cancer Therapeutics

Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Bryan Wei Chen, Wei Chen, Hui Liang, et al.

Mol Cancer Ther 2015;14:1805-1815. Published OnlineFirst May 29, 2015.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0029

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/06/04/1535-7163.MCT-15-0029.DC1

Cited articles
This article cites 50 articles, 20 of which you can access for free at:
http://mct.aacrjournals.org/content/14/8/1805.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.